VPTDF - Ventripoint Installs Whole Heart Analysis System in MD Anderson Cancer Center in Houston
(TheNewswire)
Toronto, Ontario - The Newswire - October 08, 2020 -Ventripoint Diagnostics Ltd. (" Ventripoint " orthe " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) ispleased to announce that it has remotely installed the latest versionof its whole-heart analysis system (VMS+3.0) in the University of Texas MD Anderson Cancer Center. It is one ofthe world's most respected centers devoted exclusively to cancerpatient care, research, education and prevention as recorded by beingranked one of the top two hospitals for cancer care every year for thelast 30 years.
"The first unit in the United State has beeninstalled in a cancer hospital because patients who receive therapyfor cancer often develop chronic heart conditions as the therapy istoxic to active cells, like heart muscle cells," stated Dr.George Adams, CEO and Executive Chairman of Ventripoint. "Thedeleterious effects of chemotherapy on the heart have been known fordecades - it is time to improve the monitoring of heart functionduring therapy and adjust the treatments to minimize thedamage."
This is the first installation of the VMS+3.0 in theUnited States. It is also the first VMS+3.0 unit which has beenremotely installed in the United States and so demonstrates theuniversality of the installation process.
A key addition to the VMS+3.0 was a completeworkstation to allow remote analysis of echocardiograms in viewingrooms within the hospital. Unlike Europe where the cardiologistcaptures and analyzes the images on the ultrasound unit, in the UnitedStates, sonographers collect the images into a standardized DICOM fileand uploads them to an internal server (PACS) so they can be retrievedand analyzed by a cardiologists in a viewing room. Viewing rooms areequipped with workstations and high-resolution screens to optimize theimages. Accordingly, the Company elected toincorporate a workstation into the VMS+3.0. While the VMS+3.0 isdesigned to deal with low-quality images and allow for analysis on theunit itself, it never hurts to have optimal viewing conditions.
An added benefit of the workstation is the sonographercan move on to the next patient while the analysis is being done inthe viewing room and so maximize patient throughput, machineutilization and hospital revenues. This fits the workflow within NorthAmerican hospitals and lowers the barrier to adoption of the VMS+3.0. Further, there is an existing billing code for doing a 3Dreconstruction from a 2D ultrasound on a workstation and so hospitalsin the United States can immediately bill extra for the VMS+3.0analysis of the standard echocardiogram images.
The Company estimates that 40,000 VMS+3.0 units wouldbe required to diagnose and monitor patients with hearts conditionsdue to congenital heart disease, pulmonary hypertension and cancer inNorth America and Europe. Additional units would be required for therest of the world and for other patient populations such as COVID.
AboutMD Anderson Cancer Center
MD Anderson has been oneof the top two cancer centers in the USA for decades. It receives thehighest number of research grants from the National Cancer Instituteand is the recognized leader in the diagnosis and treatment of cancer. The hospital sees approximately 1.5 million outpatients and performs615,000 imaging exams a year. Last year morethan 148,700 people sought the superior care that has made MD Andersonso widely respected -- 47,500 of whom were new patients. There weremore than 11,600 patients enrolled in 1,360-plus clinical trialsexploring innovative treatments. MD Anderson's cancer clinical trialprogram is one of the largest of its kind.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Mr . Peter Weichler,Director
Email :peter@weichler.ca
Or
Mr. Clay Chase
Email: cc@sdthc.com
Phone: 858-456-7300
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based are reasonable, undue reliance should not be placed onthe forward-looking statements and information because the Company cangive no assurance that they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2020 TheNewswire - All rights reserved.